Kiniksa Pharmaceuticals
KNSA
224 hedge funds and large institutions have $1.77B invested in Kiniksa Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 79 increasing their positions, 70 reducing their positions, and 18 closing their positions.
2,215% more call options, than puts
Call options by funds: $64.6M | Put options by funds: $2.79M
133% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 18
13% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 70
12% more capital invested
Capital invested by funds: $1.59B → $1.77B (+$187M)
10% more funds holding
Funds holding: 204 → 224 (+20)
1.21% more ownership
Funds ownership: 93.95% → 95.16% (+1.2%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.8M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$20.5M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$17.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.2M |
| 5 |
SG Americas Securities
New York
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$26.9M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$18.2M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$13.2M |
| 4 |
Walleye Capital
New York
|
-$10.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$10.7M |
KNSA Hedge Fund Activity: Q4 2025 in Review
224 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2025, worth a combined $1.77B — up 12% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new KNSA positions and 18 closed out — a net gain of 24 holders — while 79 added to existing stakes and 70 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $33.8M. The largest seller was Rubric Capital Management (New York), cutting an estimated $26.9M.
- 224 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2025, up from 204 in Q3 2025.
- Funds reported $1.77B of Kiniksa Pharmaceuticals stock for Q4 2025, up 12% quarter-over-quarter.
- 42 funds opened new Kiniksa Pharmaceuticals positions in Q4 2025 and 18 closed out, a net change of +24 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q4 2025 was Fidelity Investments, an estimated $33.8M added.
- The largest Kiniksa Pharmaceuticals seller in Q4 2025 was Rubric Capital Management (New York), an estimated $26.9M sold.
Based on aggregated 13F filings for Q4 2025.